Last reviewed · How we verify
NCT06759077
Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life
Phase 3 trial testing Dapagliflozin (DAPA) in Kidney Diseases in 126 participants. Participants enrolled and being followed up; not accepting new ones.
28 December 2024
Quick facts
| Lead sponsor | Al-Azhar University |
|---|---|
| Phase | Phase 3 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 126 |
| Start date | 28 December 2024 |
| Primary completion | 28 December 2024 |
| Estimated completion | 28 December 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Dapagliflozin (DAPA) — full drug profile →
Conditions studied
- Kidney Diseases — all drugs for Kidney Diseases →
Sponsor
Al-Azhar University
Who can join
18 and older, any sex, with Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
If this study has a cardio protective effect it will affect the mortality and morbidity of advanced CKD patients and improve their quality of life
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06759077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dapagliflozin (DAPA)
Trials testing the same drug.
- NCT06907251 — Dapagliflozin for Long COVID Syndrome · Phase 3 · not yet recruiting
- NCT06954090 — Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study · Phase 4 · enrolling by invitation
- NCT06922656 — Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Preven · Phase 4 · not yet recruiting
- NCT07120828 — The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity · Phase 4 · completed
- NCT07082114 — A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus · Phase 3 · recruiting
Other recruiting trials for Kidney Diseases
Currently open trials in the same condition.
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
- NCT07217535 — Rutgers University Study of the Genetics of Kidney Disease · recruiting
- NCT06858319 — Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. · Phase 3 · recruiting
- NCT06798909 — Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients · Phase 3 · recruiting
- NCT06912425 — Effects of an Exercise and Diet Program on Biochemistry and Body Composition in Patients With CKD in G1 and G2 Stages · NA · recruiting
Other Al-Azhar University trials
Trials by the same sponsor.
- NCT06489327 — Comparing Two Doses of Oral Melatonin as Premedication in Children Undergoing Surgery · NA · recruiting
- NCT07327918 — Effect of Epidural Needle Injection on Catheter Placement Success During Painless Labour · Phase 3 · not yet recruiting
- NCT07500194 — Quad Helix vs RME for Posterior Cross-bite in Egyptian Children · NA · not yet recruiting
- NCT07360756 — Ultrasonographic ONSD as a Predictor of PDPH in Spinal Anesthesia for Cesarean Delivery · not yet recruiting
- NCT07343570 — Comparison of Quadratus Lumborum and Combined Groin Nerve Blocks for Postoperative Analgesia After Open Inguinal Hernia · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06759077 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Al-Azhar University
- Last refreshed: 8 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06759077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing